Second Generation Analogs of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug Discovery

We previously reported that the cancer drug clinical candidate tipifarnib kills the causative agent of Chagas disease, Trypanosoma cruzi, by blocking ergosterol biosynthesis at the level of inhibition of lanosterol 14α-demethylase. Tipifarnib is an inhibitor of human protein farnesyltransferase. We...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kraus, James M., Tatipaka, Hari Babu, McGuffin, Sarah A., Chennamaneni, Naveen Kumar, Karimi, Mandana, Arif, Jenifer, Verlinde, Christophe L. M. J., Buckner, Frederick S., Gelb, Michael H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2877169/
https://ncbi.nlm.nih.gov/pubmed/20429511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm9013136
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky